12:00 AM
 | 
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Jevtana cabazitaxel regulatory update

The German Institute for Quality and Efficiency in Health Care (IQWiG) said Jevtana cabazitaxel from Sanofi provides significant additional benefit over palliative care and best supportive care for patients 65 years or older with castration-resistant prostate cancer (CRPC) for whom docetaxel is no longer an option. The...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >